Anti-prion drugs do not improve survival in novel knock-in models of inherited prion disease
PLOS Pathogens · 2024
DOI: 10.1371/journal.ppat.1012087 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2024. Verfasst von Daniel J Walsh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Cell Biology Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, United States of America. Hauptthemen laut MEDLINE: Prions, Prion Diseases, Creutzfeldt-Jakob Syndrome. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NINDS NIH HHS, National Institute of Neurological Disorders and Stroke.
Abstract (Originalsprache)
Prion diseases uniquely manifest in three distinct forms: inherited, sporadic, and infectious. Wild-type prions are responsible for the sporadic and infectious versions, while mutant prions cause inherited variants like fatal familial insomnia (FFI) and familial Creutzfeldt-Jakob disease (fCJD). Although some drugs can prolong prion incubation times up to four-fold in rodent models of infectious prion diseases, no effective treatments for FFI and fCJD have been found. In this study, we evaluated the efficacy of various anti-prion drugs on newly-developed knock-in mouse models for FFI and fCJD. These models express bank vole prion protein (PrP) with the pathogenic D178N and E200K mutations. We applied various drug regimens known to be highly effective against wild-type prions in vivo as well as a brain-penetrant compound that inhibits mutant PrP Sc propagation in vitro . None of the regimens tested (Anle138b, IND24, Anle138b + IND24, cellulose ether, and PSCMA) significantly extended disease-free survival or prevented mutant PrP Sc accumulation in either knock-in mouse model, despite their ability to induce strain adaptation of mutant prions. Our results show that anti-prion drugs originally developed to treat infectious prion diseases do not necessarily work for inherited prion diseases, and that the recombinant sPMCA is not a reliable platform for identifying compounds that target mutant prions. This work underscores the need to develop therapies and validate screening assays specifically for mutant prions, as well as anti-prion strategies that are not strain-dependent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Cell Biology Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, United States of America.
- Department of Epidemiology Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, United States of America.
- Department of Community and Family Medicine Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, United States of America.
- Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.
- Department of Biochemistry, University of Toronto, Toronto, Ontario, Canada.
- Wallenberg Center for Molecular Medicine, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
ORCID-Profile: Surachai Supattapone
Förderung
- NIGMS NIH HHS
- NINDS NIH HHS
- National Institute of Neurological Disorders and Stroke
- NIH
Zitieren
APA
Walsh, D. J., Rees, J. R., Mehra, S., Bourkas, M. E. C., Kaczmarczyk, L., Stuart, E., Jackson, W. S., Watts, J. C., & Supattapone, S. (2024). Anti-prion drugs do not improve survival in novel knock-in models of inherited prion disease. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1012087
Vancouver
Walsh DJ, Rees JR, Mehra S, Bourkas MEC, Kaczmarczyk L, Stuart E, et al. Anti-prion drugs do not improve survival in novel knock-in models of inherited prion disease. PLOS Pathogens. 2024. doi:10.1371/journal.ppat.1012087
BibTeX
@article{Walsh2024,
author = {Walsh, Daniel J and Rees, Judy R and Mehra, Surabhi and Bourkas, Matthew E C and Kaczmarczyk, Lech and Stuart, Erica and Jackson, Walker S and Watts, Joel C and Supattapone, Surachai},
title = {Anti-prion drugs do not improve survival in novel knock-in models of inherited prion disease},
journal = {PLOS Pathogens},
year = {2024},
doi = {10.1371/journal.ppat.1012087}
}
EUVIMED